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Abstract
Background/Aim: The generation of reactive oxygen
species by activated Kupffer cells (KC) may contribute to
reperfusion injury of the liver during liver transplantation
or resection. The aim of our present studies was to inves-
tigate (1) prevention of hepatic reperfusion injury after
warm ischemia by administration of the antioxidant glu-
tathione (GSH) and (2) whether GSH confers protection
through influences on KC toxicity. Methods: Isolated per-
fused rat livers were subjected to 1 h of warm ischemia
followed by 90 min of reperfusion without (n = 5) or with
GSH or catalase (n = 4–5 each). Selective KC activation by
zymosan (150 Ìg/ml) in continuously perfused rat livers
was used to investigate KC-related liver injury. Results:
Postischemic infusion of 0.1, 0.5, 1.0 and 2.0 mM GSH,
but not 0.05 mM GSH prevented reperfusion injury after
warm ischemia as indicated by a marked reduction of
sinusoidal LDH efflux by up to 83 B 13% (mean B SD;
p ! 0.05) and a concomitant significant improvement of
postischemic bile flow by 58 B 27% (p ! 0.05). A similar
protection was conveyed by KC blockade with gadolin-
ium chloride indicating prevention of KC-related reperfu-
sion injury by postischemic GSH treatment. Postisch-
emic treatment with catalase (150 U/ml) resulted in a
reduction of LDH efflux by 40 B 9% (p ! 0.05). According-
ly, catalase as well as GSH (0.1–2.0 mM) nearly com-
pletely prevented the increase in LDH efflux following
selective KC activation by zymosan in continously per-
fused rat livers. Conclusion: Postischemic administration
of GSH protects the liver against reperfusion injury after
warm ischemia. Detoxification of KC-derived hydrogen
peroxide seem to be an important feature of the protec-
tive mechanisms.
Copyright © 2002 S. Karger AG, Basel
Introduction
Warm hepatic ischemia-reperfusion injury (IRI) oc-
curs during surgical resections, liver transplantation, and
hemorrhagic shock [1–3]. This can lead to liver damage,
and in severe cases, to systemic organ dysfunction [3, 4].
Establishing blood flow to the liver as early as possible
minimizes ischemic injury. Additional damage occurs
during reperfusion [3,5]. A large body of evidence has
been accumulated for the impact of reactive oxygen spe-
cies (ROS) on reperfusion injury [6] and for Kupffer cells
(KC) as the major source of ROS formation [7]. However,
their involvement as direct toxic mediators was recently
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questioned [8, 9]. Evidence now suggests that ROS act by
influencing signal transduction processes rather than be-
ing directly involved in cell killing; they induce the activa-
tion of extracellular regulated kinases [10, 11] and redox-
sensitive transcription factors [12–14] as well as the
release of tumor necrosis factor and interleukins [15].
Furthermore, ROS have been implicated in microcircula-
tory failure after warm and cold ischemia [16–20]. Thus,
ROS induce several pivotal mechanisms of cell injury sug-
gesting a key role for ROS in the pathogenesis of reperfu-
sion injury. This concept warrants antioxidative strategies
to prevent reperfusion injury of the liver. This view is fur-
ther supported by in vivo experiments showing protective
effects of several antioxidants such as desferrioxamine
[21], superoxide dismutase (SOD) [22, 23], dimethyl sulf-
oxide [24], and precursors of glutathione such as gluta-
thione (GSH)-ethyl ester [25] and N-acetylcysteine [26,
27]. However, N-acetylcysteine failed to protect during
human liver transplantation [28], whereas the use of the
other antioxidants is limited by high costs and side effects.
In order to develop a cost-effective antioxidant therapy
without serious adverse effects recent studies focused on
the cytoprotective potential of low molecular endogenous
antioxidants, such as GSH. As demonstrated in models of
isolated rat liver perfusion and rat liver transplantation, a
high dose of GSH infusion during reperfusion protected
against the reperfusion injury following 24 h of cold pres-
ervation in University of Wisconsin solution [29, 30].
The beneficial effects of GSH administration after cold
liver preservation suggest a possible therapeutic potential
in protecting the liver against injury caused by reperfu-
sion after warm ischemia. However, reperfusion injury
after warm ischemia differs in many aspects from preser-
vation injury, e.g. the extent of KC activation and pattern
of parenchymal and nonparenchymal cell damage [1–3].
Therefore, it remains speculative whether administration
of GSH protects the liver against reperfusion injury after
warm ischemia.
Several in vivo studies demonstrated oxidation of plas-
ma GSH during reperfusion which was related in part to
the detoxification of KC-derived ROS [7, 31]. Therefore,
it was hypothesized that extracellular GSH may protect
liver cells against the vascular oxidant stress by activated
KC. Due to a possible interference with ROS of other
sources in vivo, such as accumulating neutrophils [31]
and xanthine oxidase released into the circulation [32],
direct evidence for a reduction of KC-related oxidant liv-
er injury by GSH is still lacking. Furthermore, it has not
been investigated whether protective effects of high dose
GSH treatment are related to a suppression of KC func-
tion. This aspect seems to be of particular interest since
antioxidative therapies should ideally protect liver cells
against the inflammatory response of KC without impair-
ing the vital host defense function of these cells.
Thus, the aim of our investigation was to study pre-
vention of reperfusion injury after warm ischemia by
GSH and the mechanisms involved. The effect of GSH on
reperfusion injury was studied in isolated perfused rat liv-
ers subjected to 1 h of warm ischemia. The release of lac-
tate dehydrogenase (LDH), as well as bile flow, were
determined as parameters of cell damage and of liver
function, respectively [33, 34]. In a second set of experi-
ments, we investigated the effect of GSH treatment on cell
injury following KC activation in perfused rat livers. This
model allows the selective investigation of KC-derived
liver injury in the absence of ischemic injury or concomi-
tant effects from neutrophils and extrahepatic macro-
phages [35, 36]. Using this experimental model, we stud-
ied the effect of GSH administration on KC function by
determination of zymosan particle phagocytosis and the
stimulation of glycogenolysis by KC-derived eicosanoids
[35].
Materials and Methods
Isolated Perfused Rat Liver
Male Sprague-Dawley rats (SAVO, Kisslegg, Germany) between
250 and 300 g were maintained under a 12-hour light/dark regimen
with free access to a standard diet (Altromin 1314, Altromin, Lage,
Germany) and water. The animals were anesthetized with an intra-
peritoneal injection of sodium pentobarbital (50 mg/kg body weight).
The livers were perfused in situ after cannulation of the portal vein
and hepatic veins via the right atrium and superior vena cava, respec-
tively. The livers were perfused with hemoglobin-free and albumin-
free, bicarbonate-buffered Krebs-Henseleit solution (pH 7.4, 37 °C)
gassed with 95% O2 and 5% CO2 [37]. The Krebs-Henseleit buffer
contained (in mM ) 118 NaCl, 4.8 KCl, 1.2 KH2PO4, 1.2 MgSO4 ! 7
H2O, 1.5 CaCl2, and 25 NaHCO3. The perfusion medium was
pumped through the liver with a membrane pump at a constant flow
rate of 3.0–3.5 ml ! min–1 ! g–1 liver in a nonrecirculating fashion.
The bile duct was cannulated with PE-10 tubing, and bile was col-
lected in preweighed tubes. Portal perfusion pressure was monitored
manometrically from tubing attached to the inflow cannula [38]. The
study was registered with the local animal welfare committee.
Rat livers which were continuously perfused for 120 min (n = 6)
served as a control group for livers subjected to ischemia-reperfusion
or KC activation.
Warm Ischemia-Reperfusion of Rat Livers
After cannulation of the portal vein livers were perfused for
30 min. Thereafter, the perfusion flow was turned off for 60 min to
produce warm ischemia (30 °C). During ischemia the livers were
covered with wet gaze to avoid drying [33]. The temperature during
ischemia was kept constant by means of a heating lamp. After 60 min
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of ischemia the perfusion was continued for another 90 min using
preischemic flow rates.
Seven groups (n = 4–5 each) were subjected to warm ischemia-
reperfusion as follows:
(1) untreated; 30 min of perfusion, 60 min of ischemia, and reper-
fusion for 90 min;
(2) gadolinium chloride; gadolinium chloride dissolved in saline
solution (0.9%) was administered intraperitoneally (10 mg/kg body
weight) 48 and 24 h before the experiments. Pretreated livers were
subjected to 30 min of perfusion, 60 min of ischemia and 90 min of
reperfusion.
(3–7) 0.05 mM, 0.1 mM, 0.5 mM, 1.0 mM, or 2.0 mM GSH,
respectively; 30 min of perfusion, 60 min of ischemia, and reperfu-
sion with administration of 0.05 mM, 0.1 mM, 0.5 mM, 1.0 mM, or
2.0 mM GSH during the complete reperfusion period;
(8) catalase (150 U/ml); 30 min of perfusion, 60 min of ischemia,
and administration of catalase (150 U/ml) during the complete reper-
fusion period.
GSH (Sigma Chemical Co., St. Louis, Mo., USA) was dissolved in
water. Because GSH is a weak acid, stock solutions of GSH were
adjusted to a pH of 6.5 with 1 N NaOH [29]. Stock solutions of cata-
lase (Boehringer, Germany) were prepared in 0.9% NaCl. Stock solu-
tions of GSH and catalase were infused into the portal inflow of the
perfusion system by micro-infusion pumps.
Liver Injury by Activated KC
Activation of KC was induced by the infusion of zymosan to con-
tinuously perfused rat livers. Zymosan (Sigma Chemical Co., St.
Louis, Mo., USA) consists of cell wall particles from yeast which are
selectively taken up by KC [35]. Prior to infusion, zymosan suspen-
sions were incubated at 95°C for 30 min to destroy activity of endog-
enous phospholipase A2 [35].
Seven groups (n = 4–7 each) of zymosan-treated livers were stud-
ied:
(1) zymosan; administration of zymosan (150 Ìg/ml) from 40 to
46 min after starting perfusion (n = 7);
(2–6) zymosan plus 0.05 mM, 0.1 mM, 0.5 mM, 1.0 mM or
2.0 mM GSH; administration of zymosan from 40 to 46 min and of
0.05 mM, 0.1 mM, 0.5 mM, 1.0 mM or 2.0 mM GSH from 30 to
100 min;
(7) zymosan plus catalase (150 U/ml); administration of zymosan
from 40 to 46 min and of catalase (150 U/ml) from 30 to 100 min.
Analytical Methods
Sinusoidal efflux of LDH was measured as an index of liver cell
damage [33, 37]. The activities of LDH released into the perfusate
were analyzed according to standard tests [39]. Postischemic liver
function was assessed from recovery of bile flow [34]. The content of
total GSH (reduced and oxidized fraction) in shock frozen liver sam-
ples was measured by the enzymatic recycling test using GSH reduc-
tase and 5,5)-dithio-bis-(2-nitrobenzoic acid) [40, 41]. Uptake of
zymosan was used as an indicator of particle phagocytosis by KC.
Zymosan uptake was assessed by the difference in absorbance of the
inflow and outflow perfusion buffer at 540 nm [35]. Sinusoidal efflux
of glucose was determined according to standard tests [39].
Statistics
All data are expressed as the mean B standard deviation (SD).
Statistical significance between the control group and a treated group
was determined with Student’s t-test of independent means. Com-
parisons between multiple groups were performed using one-way
analysis of variance (ANOVA); when F ratios were significant, means
were compared using Bonferroni’s test as the post hoc comparison. A
p value of 0.05 or below was considered statistically significant. The
statistical analyses were performed with SPSS software, release 6.1.3
(SPSS Inc., Chicago, Ill., USA).
Results
Effect of GSH on Liver Injury after Warm Ischemia
Cell damage was assessed by sinusoidal efflux of LDH.
Perfusion of rat livers in a continuous fashion resulted
in low LDH efflux rates which increased to only 40 B
34 mU/min ! g liver at the end of the 2-hour perfusion
period (fig. 1). When livers were subjected to 60 min of
warm ischemia, considerable cell damage occured during
reperfusion (fig. 1). LDH efflux increased rapidly within
60 min of reperfusion reaching 774 B 232 mU/min !
g liver at 90 min (total perfusion time 2 h) (fig. 1). This
cell damage was attenuated by KC blockade with gadolin-
ium chloride as indicated by the significant (p ! 0.05)
reduction of LDH efflux to only 82 B 53 mU/min ! g
liver at 90 min of reperfusion. Similar cytoprotective
effects were observed with 0.5, 1.0 and 2.0 mM GSH, but
not with 0.05 and 0.1 mM GSH (fig. 1, table 1). When
livers were reperfused with catalase (150 U/ml) LDH
efflux declined to 450 B 93 mU/min ! g liver which was
significantly (p ! 0.05) more than in livers treated with
0.5, 1.0 and 2.0 mM GSH (table 1).
Bile flow of continuously perfused livers significantly
decreased from 1.18 B 0.15 Ìl/min ! g liver initially to
0.66 B 0.09 Ìl/min ! g liver at 2 h (p ! 0.05; fig. 2). A
significantly lesser bile flow was found in livers subjected
to warm ischemia and reperfusion. Postischemic bile flow
of the untreated livers remained markedly reduced and
returned to only 0.33 B 0.05 Ìl/min ! g liver at the end
of reperfusion (fig. 2). In contrast, pretreatment with gad-
olinium chloride significantly (p ! 0.05) increased bile
flow to 0.58 B 0.07 Ìl/min ! g liver. A similar improve-
ment of bile flow to 0.52 B 0.09 Ìl/min ! g liver was
achieved by postischemic infusion of 2mM GSH (fig. 2).
Furthermore, bile flow was similarly improved by reper-
fusion with 0.1, 0.5 and 1.0 mM GSH, whereas 0.05 mM
GSH failed to influence postischemic bile flow (table 1).
In contrast, reperfusion of livers with catalase did not
affect postischemic bile flow (table 1).
In an attempt to investigate the potential mechanism
of GSH-mediated protection, we investigated effects on
portal pressure and intracellular GSH content. Portal
pressure of continuously perfused livers was 3.7 B 0.4 cm
52 Digestion 2002;66:49–57 Bilzer/Baron/Schauer/Steib/Ebensberger/
Gerbes
Fig. 1. Effect of GSH on hepatic reperfusion
injury after 1 h of warm ischemia. When liv-
ers were reperfused after 1 h of warm isch-
emia (P, n = 5), LDH efflux markedly
increased indicating considerable cell dam-
age. Administration of 2.0 mM GSH during
the 90-min reperfusion period ($ n = 5) sig-
nificantly prevented LDH increase. For
comparison, LDH release during 120 min of
continuous perfusion is indicated (j–j, n =
5). Mean B SD. * p ! 0.05 compared with
untreated livers subjected to 1 h of warm
ischemia (P).
Table 1. Concentration-dependent effect of GSH on postischemic cell damage, bile flow, portal pressure, and intra-
cellular GSH content after 1 h of warm ischemia and 90 min reperfusion
LDH efflux
mU/min ! g liver
Bile flow
Ìl/min ! g liver
Portal pressure max
cm H2O
Intracellular GSH
Ìmol/g liver
Untreated 774B232 0.33B0.05 11.4B1.7 6.8B1.0
GSH 0.05 mM 560B189 0.45B0.13 12.1B2.5 8.2B0.7
0.1 mM 299B126 0.54B0.07a 10.1B1.8 7.3B0.9
0.5 mM 130B53a 0.57B0.15 a 11.1B2.5 8.0B0.9
1.0 mM 139B74a 0.49B0.15a 10.7 B1.4 7.9B0.9
2.0 mM 129B98a 0.52B0.09a 11.7B3.2 8.4B0.7
Catalase 150 U/ml 450B93a, b 0.29B0.04 10.5B1.6 7.1B0.8
Livers were perfused for 30 min and then subjected to 60 min of warm ischemia. Sinusoidal efflux rates of LDH,
bile flow, and the intracellular GSH content were estimated after 90 min of reperfusion. Maximal portal pressure
during reperfusion was achieved after 2 min of reperfusion. Livers were perfused in the absence (untreated; n = 5) or
presence of different GSH concentrations (each n = 4–5). Data are expressed as mean B SD.
a p ! 0.05 compared with untreated livers; b p ! 0.05 compared with 0.5, 1.0 and 2.0 mM GSH.
H2O and remained stable during the 2-hour perfusion
period. In contrast, portal pressure increased immediately
after starting reperfusion reaching a maximum of 11.4 B
1.7 cm H2O within 2 min (table 1). During further reper-
fusion, portal pressure decreased and returned to baseline
after 20 min (data not shown). Administration of GSH at
any tested concentrations as well as of catalase neither
affected the maximal increase of portal pressure (table 1)
nor the return to baseline (data not shown).
At the end of the reperfusion period, the intracellular
glutathione content (sum of GSH and GSSG) of untreated
livers was determined at 6.8 B 1.0 Ìmol/g liver. Postisch-
emic treatment with 2.0 mM GSH did not affect the intra-
cellular glutathione content to 8.4 B 0.7 Ìmol/g liver.
However, a similar not significant increase was observed
at other concentrations, in particular with 0.05 mM GSH,
that showed no cytoprotection (table 1). Therefore, GSH-
mediated cytoprotection seemed not to be related to
influences on the intracellular glutathione content.
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Fig. 2. Influence of GSH treatment on post-
ischemic bile flow. During reperfusion bile
flow of untreated livers (P, n = 5) remained
significantly reduced when compared with
continuously perfused livers (j–j, n = 5).
Treatment with 2.0 mM GSH ($, n = 5) sig-
nificantly increased postischemic bile flow
but did not provide complete recovery.
Mean B SD. * p ! 0.05 compared with
untreated livers subjected to 1 h of warm
ischemia.
Table 2. Influence of different GSH
concentrations on cell damage and bile flow
following KC activation
LDH efflux
mU/min ! g liver
Bile flow
Ìl/min ! g liver
Zymosan 56B25 0.60B0.15
Zymosan plus GSH 0.05 mM 41B11 0.60B0.07
0.1 mM 21B10a 0.62B0.08
0.5 mM 15B6a 0.64B0.35
1.0 mM 20B14a 0.60B0.09
2.0 mM 10B6a 0.51B0.11
Zymosan plus Catalase 150 U/ml 11B3a 0.61B0.08
KC were activated by the administration of zymosan (150 Ìg/ml) from 40 to 46 min (n =
7). GSH was infused at different concentrations from 30 to 100 min after starting perfusion
(each group n = 4–5). Data represent LDH efflux and bile flow rates at 100 min of perfusion.
Data are expressed as mean B SD.
a p ! 0.05 compared to livers treated with zymosan only.
Effect of GSH Administration on Liver Injury
following KC Activation
KC of continuously perfused rat livers were activated
by a 6-minute infusion of zymosan (150 Ìg/ml). Sixty
minutes after zymosan infusion was started LDH efflux
markedly increased reaching 56 B 25 mU/min ! g liver
at the end of perfusion compared to only 4 B 2 mU/min
! g liver in untreated controls (p ! 0.05) (fig. 3). When
Kupffer cells were activated in the presence of 2.0 mM
GSH, sinusoidal LDH release increased to only 10 B
6 mU/min ! g liver (p ! 0.05) (fig. 3) indicating protec-
tion against Kupffer cell-related cell damage. Similar pro-
tective effects were observed with 0.1, 0.5 and 1.0 mM
GSH (table 2), but not with 0.05 mM GSH. Moreover, a
comparable reduction of LDH efflux was achieved by
treatment with catalase (150 U/ml) (fig. 3).
Following KC activation by zymosan, bile flow de-
clined from initially 1.23 B 0.17 to 0.60 B 0.15 Ìl/min !
g liver at the end of experiments (fig. 4). The decrease of
bile flow was not different from that observed in un-
treated livers (fig. 4). In addition, bile flow of zymosan-
treated livers was neither affected by GSH nor by catalase
(fig. 4, and table 2).
KC activation by zymosan resulted in a marked in-
crease of sinusoidal glucose efflux (fig. 5) which reflects
the stimulation of glycogenolysis by KC-derived eicasa-
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Fig. 3. Effect of GSH on liver cell damage
following KC activation by zymosan. KC of
continuously perfused rat livers were acti-
vated by infusion of zymosan (150 Ìg/ml) for
6 min (j, n = 7). Compared to zymosan-free
perfused controls (d, n = 6), LDH efflux
rates significantly increased 40–60 min after
KC activation. Treatment with 2.0 mM
GSH ($, n = 5), significantly reduced the
zymosan-induced LDH efflux. Mean B SD.
* p ! 0.05 compared with livers treated with
zymosan alone.
Fig. 4. Effect of GSH treatment on bile flow
following KC activation. Compared to con-
trol livers (d, n = 6), bile flow was neither
affected by the infusion of zymosan (150 Ìg/
ml) (j, n = 7) nor by the concomitant infu-
sion of 2.0 mM GSH ($, n = 5). Mean B
SD.
noids [35]. Infusion of 2 mM GSH showed no effect on
zymosan-stimulated glucose release (fig. 5). These find-
ings argue against a relevant inhibition of KC activation
or function by GSH. This concept is further supported by
the lack of effect on zymosan particle phagocytosis. When
zymosan was infused to untreated livers 60 B 6% of
administered particles were taken up. A similar zymosan
uptake was observed in livers treated with 2 mM (56 B
13%), 1 mM (50 B 16 %) and 0.5 mM GSH (60 B 14%).
Discussion
The findings of the present study clearly indicate a
therapeutic potential of postischemic GSH treatment in
protecting the liver against warm ischemia-reperfusion
injury. A large body of evidence has been accumulated for
the impact of ROS on reperfusion injury of the liver [6]
and for KC as the major source of ROS formation [7, 42]
suggesting a possible detoxification of KC-derived ROS
by GSH.
Using the model of isolated rat liver perfusion we
obtained the following main results: (1) increase of the
extracellular GSH concentration upon reperfusion as well
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Fig. 5. Effect of GSH treatment on KC-
mediated glycogenolysis. Activation of KC
by zymosan (150 Ìg/ml) (j, n = 7) resulted in
a significant increase of sinusoidal glucose
release which was not affected by treatment
with 2.0 mM GSH ($, n = 5). Mean B SD.
* p ! 0.05 compared with untreated controls
(d, n = 6).
as KC blockade by gadolinium chloride causes significant
reduction of reperfusion injury after 1 h of warm liver
ischemia; (2) administration of GSH almost completely
prevents liver injury following selective KC activation but
does not influence KC function; (3) GSH treatment
appears to reduce cell damage by KC-derived hydrogen
peroxide (H2O2) because treatment with catalase results
in a similar prevention of KC-induced cell injury.
Prevention of Reperfusion Injury by Postischemic GSH
Treatment
Administration of GSH upon reperfusion reduced si-
nusoidal LDH efflux by approximately 80%. This cyto-
protective effect was accompanied by an improvement of
liver function as assessed by a two fold increase of post-
ischemic bile flow. In contrast, infusion of GSH to contin-
uously perfused rat livers did not affect bile flow [29].
These findings argue against a choleretic effect of GSH
that might mimick improved liver function. Therefore,
increased bile flow most likely reflects improved liver
function through GSH-mediated cytoprotection. Because
postischemic GSH treatment can only protect liver cells
which are not already seriously damaged before the onset
of reperfusion, our results clearly demonstrate prevention
of reperfusion injury by GSH.
Prevention of reperfusion injury by GSH depended on
the concentration applied during reperfusion: 0.5, 1.0 and
2.0 mM, but not 0.05 and 0.1 mM, were effective. When
rat livers were subjected to 1 h of warm ischemia in vivo
plasma GSH increased to only 0.02 and 0.03 mM after 30
and 60 min of reperfusion, repectively [7]. This increase
has been regarded as an endogenous defense mechanism
in protecting liver cells from reperfusion injury [7]. In
contrast, our experiments indicate cytoprotection only at
GSH concentrations of at least 0.1 mM. Therefore, it can
be speculated that the increase of endogenous plasma
GSH in vivo is not sufficient to prevent ROS-related
reperfusion injury. This view is further supported by in
vivo experiments showing protective effects of intrave-
nously applied GSH [30] and several other antioxidants
such as desferrioxamine [21] and SOD [22, 23].
GSH is not taken up by the liver at physiological plas-
ma concentrations [43, 44], but GSH uptake into hepato-
cytes may occur at high (millimolar) extracellular concen-
trations [45]. Reperfusion of livers with GSH resulted in a
slight, but not significant, increase of the intracellular
GSH content in all treatment groups. In contrast, only
GSH concentrations 10.1 mM were protective. Thus, it
seems unlikely that influences on intracellular GSH status
contribute to cytoprotection by GSH treatment.
Prevention of KC-Induced Oxidant Injury by GSH
Activation of KC in vivo induces a complex network of
cytokines accompanied by vascular inflammation [3–5].
Furthermore, there is evidence for a pivotal role of ROS
in these pathophysiological events [5–7, 46]. In line with
these observations our results clearly demonstrate that
KC blockade by gadolinium chloride results in a nearly
complete prevention of reperfusion injury in the model of
isolated rat liver perfusion. Because gadolinium chloride
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and GSH treatment showed almost identical protective
effects (reduction of LDH efflux by approximately 80%)
our results clearly demonstrate prevention of KC-me-
diated reperfusion injury by GSH. This interpretation is
further substantiated by perfusion experiments allowing
the selective activation of KC by infusion of zymosan.
Using this experimental model KC-induced cell damage
was nearly completely reduced by the concomitant infu-
sion of catalase. Catalase selectively detoxifies H2O2.
Therefore, its protective effects indicate H2O2-mediated
liver cell damage by activated KC. Treatment of the liver
with 0.5, 1.0 and 2.0 mM GSH protected from KC-related
cell injury in a fashion similar to catalase. These findings
strongly support detoxification of H2O2 by GSH. Because
catalase and GSH are poorly taken up by liver cells their
cytoprotective action seems to take place mainly in the
extracellular space. This view is supported by earlier in
vivo experiments which demonstrated a considerable oxi-
dation of plasma GSH following KC activation [46, 47].
Thus, our results provide direct evidence for a pivotal role
of extracellular GSH in protecting liver cells against the
vascular oxidant stress produced by activated KC.
Bile flow was neither affected by the activation of KC
nor by the concomitant infusion of GSH. These findings
suggest that activated KC do not contribute to the impair-
ment of bile flow after warm or cold ischemia. In line with
this interpretation, recent studies failed to demonstrate an
effect on postischemic bile flow when KC were depleted
prior to liver transplantation [20, 48, 49]. On the other
hand, we could demonstrate a significant improvement of
postischemic bile flow in livers treated with gadolinium
chloride. Further studies are necessary to adress these
controversial effects of KC blockade after warm or cold
ischemia.
In agreement with earlier experiments [35] KC activa-
tion by zymosan resulted in a marked increase of glycoge-
nolysis as indicated by a severalfold increase of sinusoidal
glucose efflux which has been attributed to the stimula-
tion of glycogenolysis by KC-derived prostaglandins [35].
Prostaglandin-related effects thus can be regarded as a
part of the inflammatory response of activated KC. How-
ever, there was no evidence for a possible modulation of
prostaglandin production by GSH treatment because zy-
mosan-stimulated glucose efflux was not influenced by
the infusion of GSH. Therefore, protective effects of GSH
seem not to be related to influences on KC activation or
KC function. This contention is further supported by the
lack of effect of GSH treatment on zymosan particle
phagocytosis. In contrast, other protective approaches
such as the depletion of KC by dichlormethylene diphos-
phonate [48] or gadolinium chloride [7, 20, 28] as well as
KC-blockade by calcium antagonists [17] impair the vital
host defense function of KC. Based on our findings, these
problems can be avoided by direct infusion of GSH.
In conclusion, administration of GSH can be consid-
ered as a new pharmacological approach to prevent KC-
dependent and KC-independent reperfusion injury of the
liver after warm ischemia. In view of this therapeutic
potential and the apparent absence of untoward side
effects in humans following high-dose intravenous GSH
infusion [50], clinical trials can be conducted to evaluate
the therapeutic potential of GSH during human liver
transplantations and liver resections.
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